The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Description

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

Conditions

Coronary Artery Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation)

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Condition
Coronary Artery Disease
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Hospital, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Referred for a clinically indicated CT-MPI for CAD assessment
  • * Must provide written informed consent prior to any study-related procedures being performed
  • * Must be willing to comply with all clinical study procedures
  • * Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post menopausal, with minimum one (1) year history without menses.
  • * Currently taking or has taken within 48 hours the following excluded medications:
  • * ActoPlus Met (Pioglitazone + metformin)
  • * Avandamet (Rosiglitazone + metformin)
  • * Fortamet (metformin)
  • * Glucovance (Glyburide +metformin)
  • * Glucophage (metformin)
  • * Glucophage extended-release (XR) (metformin)
  • * Glumetza (metformin)
  • * Janumet (Sitagliptin + metformin)
  • * Metformin
  • * Metaglip (Glipizide + metformin)
  • * Riomet (metformin)
  • * Implanted rhythm devices (pacemaker, defibrillator)
  • * Acute psychiatric disorder
  • * Unwilling to comply with the requirements of the protocol
  • * Previously entered this study
  • * Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study
  • * Suffers from claustrophobia
  • * Impaired renal function (GFR \< 45 ml/min)
  • * Acute hypotension (\<100 mm Hg systolic)
  • * 2nd or 3rd degree atrioventricular (AV) block

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Carlo De Cecco, MD, PhD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

2024-12-31